Biocryst Pharmaceuticals (BCRX) Return on Capital Employed (2011 - 2026)

Biocryst Pharmaceuticals has reported Return on Capital Employed for 16 years, with the latest figure at 129.78% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed fell 13939.0% year-over-year to 129.78%; the trailing twelve-month figure through Mar 2026 stood at 129.78% (down 13939.0% YoY), and the FY2025 full-year result was 111.35%, up 11209.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 129.78%, down from 119.97% in the prior quarter.
• The five-year high for Return on Capital Employed was 119.97% in Q4 2025, with the low at 129.78% in Q1 2026.
• Historically, Return on Capital Employed has averaged 15.42% across 5 years, with a median of 24.64% in 2023.
• Annual changes were most pronounced in 2025 — Return on Capital Employed surged 12074 bps — and 2026, when it slumped 13939 bps.
• Biocryst Pharmaceuticals' Return on Capital Employed stood at 33.08% in 2022, then grew by 15 bps to 28.03% in 2023, then jumped by 97 bps to 0.77% in 2024, then soared by 15690 bps to 119.97% in 2025, then sank by 208 bps to 129.78% in 2026.
• The last three Return on Capital Employed figures came in at 129.78% (Q1 2026), 119.97% (Q4 2025), and 29.09% (Q3 2025), per Business Quant data.